Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310016, China.
Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Curr Oncol. 2023 Feb 22;30(3):2625-2641. doi: 10.3390/curroncol30030200.
Regional lymph node metastasis (LNM) increases the risk of distant metastasis in papillary thyroid cancer (PTC) patients. However, it remains unclear how tumor cells in PTC patients with LNM evade immune system surveillance and proceed to colonize distant organs. Here, we comprehensively characterize the tumor-infiltrating immune cell landscape in PTC with LNM. LNM-related genes include multiple important soluble mediators such as CXCL6, IL37, MMP10, and COL11A1, along with genes involved in areas such as extracellular matrix organization and TLR regulation by endogenous ligands. In PTC without LNM, the tumor infiltration of activated dendritic cells and M0 macrophages showed increases from normal cells, but with yet greater increases and correspondingly worse prognosis in PTC with LNM. Conversely, the tumor infiltration of activated NK cells and eosinophils was decreased in PTC without LNM, as compared to normal cells, and yet further decreased in PTC with LNM, with such decreases associated with poor prognosis. We further demonstrate that mutations of driver genes in tumor cells influence the infiltration of surrounding immune cells in the tumor microenvironment (TME). Particularly, patients carrying TG mutations tend to show increased filtration of M2 macrophages and activated NK cells in the TME, whereas patients carrying HRAS mutations tend to show reduced filtration of M0 macrophages and show enhanced filtration of activated dendritic cells in the TME. These findings increase our understanding of the mechanisms of regional lymph node metastasis in PTC and its associated tumor microenvironment, potentially facilitating the development of personalized treatment regimens to combat immunotherapy failure.
区域淋巴结转移(LNM)增加了甲状腺乳头状癌(PTC)患者发生远处转移的风险。然而,目前尚不清楚 PTC 伴 LNM 患者的肿瘤细胞如何逃避免疫系统的监视并转移到远处器官。在这里,我们全面描述了 LNM 相关的 PTC 肿瘤浸润免疫细胞景观。LNM 相关基因包括多个重要的可溶性介质,如 CXCL6、IL37、MMP10 和 COL11A1,以及涉及细胞外基质组织和内源性配体 TLR 调节等领域的基因。在无 LNM 的 PTC 中,与正常细胞相比,激活的树突状细胞和 M0 巨噬细胞的肿瘤浸润增加,但在有 LNM 的 PTC 中,其增加幅度更大,预后更差。相反,与正常细胞相比,无 LNM 的 PTC 中激活的 NK 细胞和嗜酸性粒细胞的肿瘤浸润减少,而在有 LNM 的 PTC 中,这种减少与预后不良相关。我们进一步证明,肿瘤细胞中驱动基因的突变会影响肿瘤微环境(TME)中周围免疫细胞的浸润。特别是,携带 TG 突变的患者在 TME 中更倾向于显示 M2 巨噬细胞和激活的 NK 细胞的滤过增加,而携带 HRAS 突变的患者在 TME 中更倾向于显示 M0 巨噬细胞滤过减少,同时激活的树突状细胞滤过增加。这些发现增加了我们对 PTC 区域淋巴结转移及其相关肿瘤微环境机制的理解,可能有助于开发针对免疫治疗失败的个体化治疗方案。